RxDoctor Payments Data

Benjamin Schrubbe, MD

Family Medicine · Fairhope, ALNPI 1306895289

Payments from drug & device makers

$14,094in general payments, 2019–2025

Across 874 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$910
  • Johnson & Johnson$626
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,96299%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)110$1,724
Novo Nordisk122$1,653
Pfizer76$1,269
Lilly USA, LLC77$1,072
AstraZeneca49$910
Johnson & Johnson47$626
Amgen38$560
Merck40$530
Boehringer Ingelheim32$521
Bayer21$456
GSK32$444
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$336
Axsome Therapeutics, Inc.15$303
Novartis16$231
Corcept Therapeutics7$224
Astellas Pharma US Inc7$209
Takeda Pharmaceuticals U.S.A., Inc.14$204
Antares Pharma, Inc.10$195
Tris Pharma Inc10$168
Amarin Pharma, Inc.8$163
Corium, LLC8$141
Lundbeck LLC5$123
Biohaven Pharmaceutical Holding Company Ltd.6$116
Otsuka America Pharmaceutical, Inc.6$103
Teva Pharmaceuticals USA, Inc.6$102
Exact Sciences5$93
Shire North American Group Inc7$92
Idorsia Pharmaceuticals US Inc5$89
Supernus Pharmaceuticals, Inc.5$78
Mylan Specialty L.p.4$73
Tolmar, Inc.4$66
Phathom Pharmaceuticals, Inc.5$66
Seqirus USA Inc2$64
Ironshore Pharmaceuticals Inc.3$61
Boston Scientific2$58
Hikma Pharmaceuticals USA4$57
Esperion Therapeutics, Inc.4$57
Biohaven Pharmaceuticals, Inc.3$55
Optinose US, Inc.3$52
Daiichi Sankyo Inc.3$51
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$50
Inspire Medical Systems, Inc.1$50
Sumitomo Pharma America, Inc.3$48
Currax Pharmaceuticals LLC3$43
Neos Therapeutics, LP3$43
Sanofi-aventis U.S. LLC2$42
Abbott2$40
Jazz Pharmaceuticals Inc.2$38
Viatris Specialty LLC2$36
Sanofi Pasteur Inc.2$34
Organon1$30
Acadia Pharmaceuticals Inc1$27
Shield Therapeutics Inc1$26
Xeris Pharmaceuticals, Inc.1$20
Eisai Inc.1$19
Paratek Pharmaceuticals, Inc.1$18
Bristol Myers Squibb1$18
Medtronic1$18
Ironwood Pharmaceuticals, Inc1$16
Halozyme Inc1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,094 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$157,182
Medicare patients
261
Services billed
4,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$85,798
OzempicSemaglutide71$79,780
TrulicityDulaglutide36$49,112
EliquisApixaban56$45,261
FarxigaDapagliflozin Propanediol50$42,904
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$26,136
JardianceEmpagliflozin37$22,379
VascepaIcosapent Ethyl34$14,914
LinzessLinaclotide17$11,093
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,781
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen341$7,611
Tresiba Flextouch U-100Insulin Degludec12$6,913
Icosapent Ethyl18$5,857
Breo ElliptaFluticasone/Vilanterol14$5,547
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$5,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,072$134,910116 claims
Novo NordiskOzempic$1,653$79,78071 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$910$56,75977 claims
PfizerEliquis$1,269$45,26156 claims
GSKTrelegy Ellipta, Breo Ellipta$444$31,68347 claims
Boehringer IngelheimJardiance$521$22,37937 claims
AbbVieLinzess, Synthroid$1,724$13,60239 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$204$4,19111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →